PRA Adds Large Molecule Capabilities to US Laboratory - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
PRA Adds Large Molecule Capabilities to US Laboratory

Source: Company News Release

PRA, a leading clinical research organization, today announced that in addition to offering full-service bioanalytical capabilities in its Assen, The Netherlands, laboratory, it will add immunochemistry services in its Lenexa, Kan., laboratory. PRA is now the only company in the world with full-service bioanalytical capabilities near its clinics to support rapid results from Phase I clinical studies in both the U.S. and Europe, facilitating complex and adaptive study design.

“By expanding our services to large molecule bioanalysis, we can now support all types of clinical trials,” said Chad Briscoe, Ph.D, PRA executive director, Science & Innovations, Bioanalytical Laboratories. “It is an important addition to our services because the contribution of large molecules in drug research and the development of biosimilars have increased rapidly over the past few years.”  

PRA's Early Development Services group is committed to the highest standards of clinical excellence and scientific expertise. With more than 1,000 staff, 500 beds, eight clinics and two laboratories, it is the most comprehensive early development organization in the world. From its state-of-the-art facilities, the group provides the pharmaceutical and biotech industries with the unique scientific environment required for complex compound development and testing in both healthy volunteers and patients. In addition, PRA’s harmonized laboratory facilities in The Netherlands and the U.S. are situated close to the clinical facilities and are configured to fully support all clinical study requirements.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here